Table 3. Summary of the trials involving Rituximab.

Drug	Significant Trials	Findings
Rituximab – Chimeric anti-CD20 monoclonal antibody	EXPLORER TRIAL [19]	-Patients with moderate to severe SLE did not achieve primary endpoint. -Showed reduced risk and frequency of flares - A beneficial effect of the primary endpoint was observed in the African American and Hispanic subgroups.
	LUNAR TRIAL [20]	-Patients with class 111 or 1V lupus nephritis were randomized. -Primary endpoint was not achieved. - Significant improvement in complement levels and Anti-DsDNA levels were observed among the Rituximab treated group.